secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001437749-25-033949
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia announces first patient enrolled at Henry Ford Health in Phase 3 CardiAMP HF II trial
--------------------------------------------------------------------------------

- First patient enrolled at Henry Ford Health in Phase 3 CardiAMP HF II trial for ischemic heart failure with reduced ejection fraction.
- Prior CardiAMP HF study showed reduced mortality and major adverse cardiac events in patients with elevated NTproBNP.
- Phase 3 is a 250-patient randomized, placebo-controlled confirmatory study using a three-tier composite primary endpoint.
- Primary endpoint composite: all-cause death, nonfatal MACE, and validated quality of life measure.
- CEO notes ~2 million US and EU patients with NYHA Class II/III symptoms who may benefit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925033949/0001437749-25-033949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925033949/bcda20251110_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-033949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer